Semaglutide: the complete guide
Semaglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management. It slows gastric emptying, enhances insulin secretion, and reduces appetite.
How Semaglutide works
Semaglutide mimics endogenous glucagon-like peptide-1 (GLP-1), binding to GLP-1 receptors in the pancreas (boosting glucose-dependent insulin release) and in the hypothalamus (suppressing appetite).
Typical Semaglutide dosage
Commonly reported research ranges: Titration: 0.25 mg (250 mcg) → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg weekly.
Dose should always be individualized. Factors that influence it include bodyweight, research goal, tolerance, and specific compound batch. The information below is educational, not a prescription.
How to reconstitute Semaglutide
A widely used reconstitution for a 5 mg vial is 2 ml of bacteriostatic water. With a typical 250 mcg dose this works out to the unit count shown in the calculator below.
Half-life and administration frequency
Approximately 7 days (once-weekly dosing).
This half-life informs how often Semaglutide is typically dosed. Shorter half-lives usually mean more frequent dosing to maintain plasma levels; longer half-lives allow daily, weekly, or less-frequent administration depending on the compound.
Plot it: the Semaglutide half-life and pharmacokinetics chart shows accumulation, steady state, peak and trough for any cadence. Converting between mcg, mg and IU? Use the peptide dose converter.
Reported side effects
- Nausea (very common, especially during dose escalation)
- Constipation or diarrhea
- Fatigue
- Injection-site reactions
- Rare: pancreatitis, gallbladder issues
This list reflects effects reported in available literature or user logs. It is not exhaustive. Adverse reactions should be discussed with a qualified clinician.
Common Semaglutide stacks
- Often used alone; some users combine with cagrilintide in research settings
Full editorial stack guides featuring Semaglutide:
Semaglutide + Tesamorelin
Recomposition alongside GLP-1 fat loss, targeting visceral fat, users losing too much lean mass on Semaglutide alone.
Semaglutide + Cagrilintide
Users who plateau on semaglutide alone, pursuing tirzepatide-range weight loss without switching classes, clinical replications of the CagriSema program.
Semaglutide compared with
Side-by-side breakdowns against other peptides in the same class or category.
Related peptides
Compounds that come up alongside Semaglutide — because they are compared with it, stacked with it, or sit in the same category.
Tirzepatide
Head-to-head with Semaglutide — Dual GIP / GLP-1 receptor agonist.
Retatrutide
Head-to-head with Semaglutide — Triple GIP / GLP-1 / glucagon receptor agonist.
Tesamorelin
Commonly run alongside Semaglutide — GHRH analog.
Cagrilintide
Commonly run alongside Semaglutide — Long-acting amylin analog.
Liraglutide
Also metabolic / glp-1 — GLP-1 receptor agonist.
Browse the full peptide glossary, the peptide stack guides, or the reconstitution calculator.
Storage and handling
Lyophilized stable refrigerated. Reconstituted: refrigerated 2–8 °C, use within 28 days.
FDA and regulatory status
FDA approved as Ozempic (type 2 diabetes), Wegovy (obesity), Rybelsus (oral T2D). Compounded semaglutide is not FDA approved and is under active FDA scrutiny.
Semaglutide clinical trials and evidence
For clinical-trial and primary-literature context, start with the sources below. We prioritize official drug labels, ClinicalTrials.gov records, and PubMed-indexed literature when available.
- STEP and SUSTAIN trial programs (ClinicalTrials.gov) — ClinicalTrials.gov
Track your Semaglutide protocol on iPhone
Peptide Protocol logs every dose, calculates reconstitution for you, and keeps your full protocol on one calm screen.
See the app →Frequently asked questions
What is Semaglutide?
Semaglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management. It slows gastric emptying, enhances insulin secretion, and reduces appetite.
How does Semaglutide work?
Semaglutide mimics endogenous glucagon-like peptide-1 (GLP-1), binding to GLP-1 receptors in the pancreas (boosting glucose-dependent insulin release) and in the hypothalamus (suppressing appetite).
What is a typical Semaglutide dose?
Commonly reported ranges are Titration: 0.25 mg (250 mcg) → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg weekly. This is research information, not a recommendation — dosing should be individualized under clinical guidance.
What is the half-life of Semaglutide?
Approximately 7 days (once-weekly dosing). This influences how often it is administered.
How do you reconstitute Semaglutide?
A common approach is to add 2 ml of bacteriostatic water to a 5 mg vial. Use the reconstitution calculator for exact unit counts.
What are the side effects of Semaglutide?
Nausea (very common, especially during dose escalation); Constipation or diarrhea; Fatigue; Injection-site reactions; Rare: pancreatitis, gallbladder issues.
Is Semaglutide FDA approved?
FDA approved as Ozempic (type 2 diabetes), Wegovy (obesity), Rybelsus (oral T2D). Compounded semaglutide is not FDA approved and is under active FDA scrutiny.
Are there clinical trials for Semaglutide?
Registered or published clinical-trial sources for Semaglutide are listed in the references section below. Evidence depth varies widely by compound, so check the cited trial registries and primary literature before relying on any claim.
References
- Ozempic / Wegovy / Rybelsus prescribing information (FDA Drugs@FDA) — U.S. Food and Drug Administration. Official FDA-approved labeling for semaglutide products
- STEP and SUSTAIN trial programs (ClinicalTrials.gov) — ClinicalTrials.gov. Phase 3 obesity (STEP) and diabetes (SUSTAIN) trial records
- Semaglutide clinical literature (PubMed) — National Library of Medicine. Primary literature on GLP-1 receptor agonist pharmacology and outcomes
Sources listed above were used to verify the claims on this page. See our editorial policy for how we source information.
Educational use only. Peptide Protocol is an informational tool. Nothing on this page constitutes medical advice. Many peptides are prescription-only or restricted in your jurisdiction. Always consult a licensed healthcare professional before injecting any compound.